EUVIMEDOpdag EUVIMED
Beobachtungsstudie

Risk of bleeding with factor Xa inhibitors versus unfractionated heparin in patients with acute kidney injury

Bianca Aprilliano, Christopher Giuliano, Renee Alexander Paxton, Stephanie B Edwin iD

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · 2023

DOI: 10.1002/phar.2759 ↗

At a glance

Beobachtungsstudie in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2023. Written by Bianca Aprilliano and 3 co-authors. Institution: Department of Pharmacy, Ascension St. John Hospital, Detroit, Michigan, USA. Major MEDLINE topics: Venous Thromboembolism, Acute Kidney Injury. 19 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Study Objective To compare bleeding and thromboembolic events in patients receiving therapeutic doses of apixaban or rivaroxaban versus unfractionated heparin (UFH) in patients with acute kidney injury (AKI).

Design

Single‐center, retrospective, observational study.

Setting

Ascension St. John Hospital in Detroit, Michigan. Patients Hospitalized adult patients who received therapeutic doses of factor Xa inhibitors ( n = 250) or UFH ( n = 250) for at least 24 h in the setting of AKI. Measurements and Main Results After adjusting for confounding factors, patients who received a factor Xa inhibitor experienced a lower risk of composite major and clinically relevant nonmajor bleeding (CRNMB) events compared with UFH (OR: 0.57, 95% CI: 0.34–0.94; p = 0.03). There was a significantly decreased risk of CRNMB events in the factor Xa inhibitor group (OR: 0.55, 95% CI: 0.33–0.91, p = 0.02); however, no significant differences in major bleeding or venous thromboembolism (VTE) were noted.

Conclusions

Our results suggest that it may be preferable to continue patients in AKI on factor Xa inhibitors versus transitioning to UFH due to the lower risk of bleeding events.

Subjects

MeSH terms (MEDLINE)

Venous ThromboembolismAcute Kidney InjuryAdultHumansHeparinFactor Xa InhibitorsRetrospective StudiesHemorrhageFibrinolytic AgentsAnticoagulantsHeparin, Low-Molecular-Weight

Author keywords

acute kidney injuryapixabanrivaroxabanunfractionated heparin

Substances

HeparinFactor Xa InhibitorsFibrinolytic AgentsAnticoagulantsHeparin, Low-Molecular-Weight

Authors and institutions

  • Department of Pharmacy, Ascension St. John Hospital, Detroit, Michigan, USA.
  • Department of Pharmacy, Wayne State University Eugene Applebaum Applebaum College of Pharmacy and Health Sciences, Detroit, Michigan, USA.

ORCID profiles: Stephanie B Edwin

Cite

APA

Aprilliano, B., Giuliano, C., Paxton, R. A., & Edwin, S. B. (2023). Risk of bleeding with factor Xa inhibitors versus unfractionated heparin in patients with acute kidney injury. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. https://doi.org/10.1002/phar.2759

Vancouver

Aprilliano B, Giuliano C, Paxton RA, Edwin SB. Risk of bleeding with factor Xa inhibitors versus unfractionated heparin in patients with acute kidney injury. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2023. doi:10.1002/phar.2759

BibTeX
@article{Aprilliano2023,
  author = {Aprilliano, Bianca and Giuliano, Christopher and Paxton, Renee Alexander and Edwin, Stephanie B},
  title = {Risk of bleeding with factor Xa inhibitors versus unfractionated heparin in patients with acute kidney injury},
  journal = {Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
  year = {2023},
  doi = {10.1002/phar.2759}
}
Start for free →